VETOQUINOL (VETO) AI Stock Analysis

• Market Cap: €972.11M
• Dividend Yield: 1.06%
• Average Volume (3M): 5.40K
• Price to Earnings (P/E): 8.7
• Beta (1Y): 0.44
• Revenue Growth: -0.95%
• EPS Growth: 27.67%
• Country: FR
• Employees: 2,519
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.13
• Shares Outstanding: 11,881,902
• 10 Day Avg. Volume: 4,099
• 30 Day Avg. Volume: 5,401
• PEG Ratio: 2.53
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 1.64
• P/FCF Ratio: 12.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 5.27
• Revenue Forecast (FY): €538.20M

• Rating: 72 Outperform
• Price Target: €96.00 ▲(13.74% Upside)
• Action: Reiterated Date: 10/30/25
• Date: Action: Reiterated 10/30/25

VETOQUINOL's overall stock score reflects strong financial performance and fair valuation. The company's solid profitability and efficient operations are key strengths. Technical analysis presents mixed signals, with potential downward pressure indicated by RSI. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Diversified product portfolio & global reach

A broad product mix across companion animals, livestock and aquaculture plus global distribution reduces reliance on a single market. This durable diversification smooths revenue cyclicality, enables cross‑selling, and supports balanced R&D allocation and long‑term resilience.

Strong profitability and efficient operations

Consistently healthy margins and operational efficiency indicate sustainable competitive advantages in production and cost control. Strong profitability generates internal funds for R&D and capex, supports dividends, and provides a buffer against input cost swings over multiple quarters.

Solid balance sheet with low leverage

Low debt‑to‑equity and a strong equity ratio lower solvency risk and preserve financial flexibility. This capital structure supports opportunistic investments, M&A and working capital needs during industry cycles without excessive refinancing or covenant pressure.

Negative Factors

Weak reported revenue trend

A reported ~-94.5% revenue change signals a material top‑line contraction that, if persistent, erodes scale economies and margin sustainability. Sustained revenue weakness would constrain R&D funding, limit reinvestment capacity and impair long‑term cash generation.

Declining free cash flow growth

Slowing free cash flow growth reduces internal funding available for capex, product development and shareholder returns. Over several months this limits strategic flexibility, may force external financing for growth initiatives, and raises sensitivity to operating shocks.

Rising liabilities require monitoring

Even from a low leverage base, an upward trend in total liabilities can tighten financial flexibility and increase interest or covenant exposure. If continued, it may reduce capacity for acquisitions or share returns and elevate refinancing risk in adverse market conditions.

VETOQUINOL Business Overview & Revenue Model

Company Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

How the Company Makes Money

VETOQUINOL generates revenue primarily through the sale of its veterinary pharmaceuticals and health products. The company's revenue model is based on a diversified portfolio that includes prescription medications, over-the-counter products, and nutritional solutions for both companion animals and livestock. Key revenue streams include product sales in established markets across Europe, North America, and Asia-Pacific, as well as emerging markets where animal health is gaining attention. Significant partnerships with veterinary clinics, animal health distributors, and livestock producers also contribute to VETOQUINOL's earnings, as these collaborations enhance market reach and product accessibility. Additionally, the company invests in research and development to innovate new products, which can lead to increased sales and market share.

VETOQUINOL Financial Statement Overview

Summary

VETOQUINOL demonstrates strong financial performance with robust profitability and efficient operations. The income statement shows healthy profit margins and consistent revenue growth. The balance sheet is solid with low leverage, though a slight increase in liabilities needs monitoring. Cash flows are positive, but there's room for improvement in cash flow growth.

Income Statement

VETOQUINOL shows strong financial performance in its income statement. The gross profit margin is healthy, reflecting efficient production and service delivery. There is consistent revenue growth with a notable increase in net income, signaling robust profitability. EBIT and EBITDA margins are also solid, indicating effective operational management and cost control. However, the revenue growth rate has been moderate, highlighting the need for further expansion in market reach.

Balance Sheet

The balance sheet of VETOQUINOL is solid, characterized by a low debt-to-equity ratio, which underscores the company's prudent financial management and low leverage risk. The return on equity is commendable, showcasing effective use of shareholders' equity to generate profits. The equity ratio is strong, demonstrating a solid capital structure. Nonetheless, a slight increase in total liabilities warrants monitoring to maintain financial stability.

Cash Flow

VETOQUINOL maintains a positive cash flow position, with stable operating cash flows and a healthy free cash flow to net income ratio. The operating cash flow to net income ratio indicates efficient cash generation relative to net income. However, there has been a decrease in free cash flow growth rate, which suggests a need for enhanced cash flow management to support future investments and operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	532.39M	539.20M	529.27M	539.78M	521.27M	427.47M
Gross Profit	184.09M	387.45M	291.38M	172.37M	167.37M	123.98M
EBITDA	108.53M	114.08M	112.33M	103.46M	116.86M	59.29M
Net Income	59.96M	58.69M	55.56M	47.99M	62.86M	19.22M
Balance Sheet
Total Assets	725.82M	744.13M	692.23M	651.85M	624.56M	646.09M
Cash, Cash Equivalents and Short-Term Investments	181.51M	206.33M	147.46M	93.71M	69.00M	129.44M
Total Debt	17.74M	21.12M	17.63M	17.42M	15.38M	124.86M
Total Liabilities	158.29M	168.20M	165.12M	167.19M	183.21M	274.26M
Stockholders Equity	567.45M	575.84M	527.01M	484.57M	441.26M	371.75M
Cash Flow
Free Cash Flow	55.76M	68.15M	70.38M	39.90M	56.76M	-53.45M
Operating Cash Flow	73.39M	85.83M	89.39M	62.39M	89.17M	92.01M
Investing Cash Flow	-21.14M	-15.65M	-18.88M	-21.52M	-33.45M	-145.14M
Financing Cash Flow	-27.15M	-16.03M	-15.50M	-16.06M	-120.31M	102.20M

VETOQUINOL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 84.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Negative. The current price of 84.4 is below the 20-day moving average (MA) of 86.09, below the 50-day MA of 85.39, and above the 200-day MA of 77.78, indicating a neutral trend. The MACD of -0.67 indicates Positive momentum. The RSI at 33.86 is Neutral, neither overbought nor oversold. The STOCH value of 54.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:VETO.

VETOQUINOL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIRP	75 Outperform	€2.90B	8.13	12.92%	0.41%	6.97%	-5.59%
VETO	72 Outperform	€972.11M	8.71	10.80%	1.06%	-0.95%	27.67%
BOI	69 Neutral	€473.00M	8.56	5.22%	3.95%	4.80%	-18.25%
IPN	67 Neutral	€13.61B	22.37	10.82%	1.17%	9.57%	-34.30%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
MEDCL	49 Neutral	€759.14M	-12.22	―	―	166.31%	43.80%
VLA	47 Neutral	€808.47M	-4.53	-55.53%	―	13.48%	-1299.09%